September 30, 2025 - Acadia Story
I am proud to announce a new chapter in Acadia’s story – the launch of our corporate rebrand. This evolution goes beyond a new look and feel for our organization to establish a foundation that aligns Acadia with who we are, what we stand for, and where we are headed as a company – becoming a global biotech powerhouse.
Since our founding, Acadia has taken on tough challenges in advancing therapies to address areas of unmet need. We established our identity as a CNS company with the launch of our first commercial product – a treatment for Parkinson’s disease-related hallucinations and delusions. We then expanded into rare disease with the approval of a second commercial product to treat Rett syndrome. Today we are a global company committed to advancing care in neurological disorders and rare diseases: areas that are often overlooked, where patients and families are underserved, and solutions are limited. Our new brand identity builds on this foundation. It expresses our hope for the future: one that is bright, purposeful, and visionary, defined by the relentless pursuit of transformative science.
Why Now?
The world of neuroscience and rare disease medicine has entered a new era. Advances in genetics, digital health analytics, and biomarker-enabled precision medicine are reshaping what’s possible. Yet the journey from discovery to access remains challenging, especially for patients living with conditions that others have considered too complex, too rare, or too risky to tackle.
In this environment, standing still is not an option. We recognize the need to convey more clearly who we are: a company that not only embraces complexity but sees it as the key to progress. A company committed to transforming scientific promise into therapies that make the difference for those impacted by neurological disorders and rare diseases.
Our rebrand reflects that commitment through an updated identity that is optimistic and grounded in expertise. It’s a symbol of our dedication to patients and caregivers, and to the extraordinary science that fuels hope.
Grounded in Our Values
This rebrand elevates the values that define how we show up for patients and their families, for partners, and for each other:
- Start with Them. We put underserved patients first. Their needs guide every decision we make, because what matters to them matters most to us.
- Listen to Learn. We stay curious. Drawing on insights from patients, partners, and each other, we take smarter, more compassionate approaches to advance care.
- See the Promise. We see potential where others don’t. With bold science and a shared vision, we take on tough challenges because breakthroughs require courage.
- Make it Happen. We go all in. We move forward together and show up with care, because people count on us.
What this Means for Patients and Partners
Our new brand is a promise to patients, caregivers, and clinicians that we will never lose sight of the human side of science.
It means knowing that we see them, we hear them, and we are driven by their needs. And it signals our readiness to collaborate, to innovate, and to bring forward therapies that make a difference.
Looking Ahead
This rebrand is a catalyst. It sets the stage for the next era of Acadia, as we accelerate and expand upon a pipeline designed to tackle urgent needs in neurological and rare diseases.
And it underscores our intention to use our insights from prior successes in neuropsychiatry and rare neurological conditions to expand into adjacent therapeutic areas. These include Alzheimer’s and Lewy body dementia-associated psychosis, major depressive disorder, Huntington’s disease and others, as well as rare diseases in areas beyond neuroscience.
We know the road ahead will not be simple. The science is complex, the challenges are significant, and the stakes are high. But that is exactly why we are here.
